Compare TY & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TY | NVAX |
|---|---|---|
| Founded | 1929 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | N/A | 1996 |
| Metric | TY | NVAX |
|---|---|---|
| Price | $34.83 | $8.93 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 34.4K | ★ 4.4M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ 4.78 | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.29 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $30.53 | $6.20 |
| 52 Week High | $36.03 | $11.85 |
| Indicator | TY | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 46.20 |
| Support Level | $34.20 | $8.89 |
| Resistance Level | $34.79 | $9.02 |
| Average True Range (ATR) | 0.64 | 0.60 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 28.68 | 36.52 |
Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.